Skip to search formSkip to main contentSkip to account menu

UK-427,857

Known as: UK 427,857, UK-427857 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

maraviroc

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists
In addition to being an important receptor in leukocyte activation and mobilization, CCR5 is the essential coreceptor for human… 
2007
2007
Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor.
Highly Cited
2006
Highly Cited
2006
Potent Antiviral Synergy between Monoclonal Antibody and Small-Molecule CCR5 Inhibitors of Human Immunodeficiency Virus Type 1
ABSTRACT The chemokine receptor CCR5 provides a portal of entry for human immunodeficiency virus type 1 (HIV-1) into susceptible… 
Highly Cited
2005
Highly Cited
2005
Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity
ABSTRACT Maraviroc (UK-427,857) is a selective CCR5 antagonist with potent anti-human immunodeficiency virus type 1 (HIV-1… 
Highly Cited
2005
Highly Cited
2005
SPECIES DIFFERENCES IN THE DISPOSITION OF THE CCR5 ANTAGONIST, UK-427,857, A NEW POTENTIAL TREATMENT FOR HIV
UK-427,857 (4, 4-difluoro-N-{(1S)-3-[exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1… 
Highly Cited
2005
Highly Cited
2005
Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human.
Review
2005
Review
2005
Emerging anti-HIV drugs
There are now exactly 20 anti-HIV drugs licenced (approved) for clinical use, and > 30 anti-HIV compounds under (pre)clinical… 
Highly Cited
2005
Highly Cited
2005
A pharmacokinetic‐pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc
Review
2005
Review
2005
CCR5 Antagonists: Host-Targeted Antivirals for the Treatment of HIV Infection
The human chemokine receptors, CCR5 and CXCR4, are potential host targets for exogenous, small-molecule antagonists for the… 
Review
2004
Review
2004
New advances in HIV entry inhibitors development.
Considerable advances have been made in the last years in the design of derivatives acting as inhibitors of HIV entry and fusion… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)